Live Breaking News & Updates on Humoral Immunology
Stay updated with breaking news from Humoral immunology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (National Steering Committee for Therapeutic Trials and other Research on Covid-19). ....
This Clinical Trial Has Been Awarded National Priority Research Status by the French Government SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company ....
Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). ....
Results are available as preprint and have been submitted in an international peer-reviewed journal. https://www.biorxiv.org/content/10.1101/2022.04.01.486719v1 SpikImm expects to initiate ....
Truffle Capital & The Institut Pasteur Create SpikImm to Develop Monoclonal Antibodies as an Innovative Treatment For Covid-19 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005708/en/ Monoclonal antibody therapy is one of the most innovative ways currently available to treat Covid-19 patients and prevent severe forms of the disease from developing. This immunotherapy offers several therapeutic advantages which have already been proven in clinical trials. Antibodies developed by SpikImm have been generated in the laboratory of Humoral Immunology at the Institut Pasteur through an innovative process enabling the screening and selection of human SARS-CoV-2 neutralizing antibodies. An international patent application has been filed by the Institut Pasteur. ....